drugset / Trial / NCT01887171

Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus

NCT01887171

RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine whether the Tacrolimus added to histidine-tryptophan-ketoglutarate (HTK) solution given through intraportal and intraarterial infusion during back-table procedure is capable of reducing the degree of early allograft liver dysfunction, as assessed by postoperative levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), during first 7 postoperative days and by serum and histochemical markers of liver injury and inflammation.

Timeline

Start
2013-07
Primary completion
2014-07
Completion
2014-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 20 ng/ml Other